Evofem Biosciences, Inc. (NASDAQ:EVFM) today announced that Phexxi™ (lactic acid, citric acid and potassium bitartrate), the first and only non-hormonal prescription vaginal gel is now available in the United States for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.
Approved by the U.S. Food and Drug Administration (FDA) on May 22, 2020, Phexxi is a vaginal pH modulator designed to maintain vaginal pH within the normal range of 3.5 to 4.5 – an acidic environment that is inhospitable to sperm. Phexxi will be commercially available in a box containing 12 individually wrapped Phexxi applicators. For more information, visit www.phexxi.com.
"As a leader of innovation in women's healthcare, we are thrilled to usher in a new era of sexual and reproductive health with the launch of Phexxi," said Saundra Pelletier, Evofem Biosciences' Chief Executive Officer. "Millions of women have either settled for less or completely opted out of using birth control because they have had enough with side effects and lack of control. Today, we are fulfilling Evofem's mission of delivering a novel contraceptive option that women have been waiting for."
Evofem is also launching the Phexxi Concierge Experience, a comprehensive woman-centric telemedicine support system to help ensure Phexxi is accessible to all women who need it. This robust offering of services is designed to help women quickly consult with a healthcare provider to secure a Phexxi prescription, determine their insurance coverage and/or out-of-pocket costs, receive counseling support and refill reminders, and fill their prescription through their local neighborhood pharmacy or our mail order pharmacy partner, KnippeRx, that is expected to deliver Phexxi right to their door.
Evofem is committed to facilitating access to Phexxi for women who are not covered by government or private health plans and will provide a financial assistance program to enable access to Phexxi for eligible women. Through this program, eligible patients may pay a $0 co-pay for their first prescription of Phexxi, and as little as $30 on future prescriptions.